News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Dec 07, 2020 7:30am EST

Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Nov 18, 2020 7:00am EST

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

Nov 16, 2020 8:00am EST

Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 12, 2020 4:01pm EST

Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Oct 29, 2020 8:00am EDT

Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020

Oct 22, 2020 8:00pm EDT

Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering

Oct 06, 2020 7:00am EDT

Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Sep 25, 2020 7:00am EDT

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical

Sep 10, 2020 4:05pm EDT

Brickell Biotech to Participate in September Virtual Investor Conferences

Sep 08, 2020 7:30am EDT

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.